H.C. Wainwright analyst Andrew Fein please expalin..:)Globe says Bellus Health rated "buy" in new coverage 2020-06-29 08:28 ET - In the News
The Globe and Mail reports in its Saturday, June 27, edition that H.C. Wainwright analyst Andrew Fein rates Bellus Health ($9.57) "buy" in new coverage (all figures U.S.). The Globe's David Leeder writes that Mr. Fein targets the shares at $28, which is $12.14 above the consensus. Mr. Fein says he is bullish on Bellus ahead of the imminent release of top-line data from the RELIEF Trial for its BLU-5937 treatment for chronic cough. He says the drug's "differentiated profile" makes it a "formidable" candidate, suggesting "competitor readouts position BLU-5937 as best-in-class." Mr. Fein says in a note: "Based on our analysis of the current therapeutic landscape and BLU-5937's mechanism of action, coupled to its PK/PD profile, we view a positive outcome for the RELIEF study well within reach. As we await data from the RELIEF trial, we continue to be encouraged by the increasing body of evidence validating the use of P2X3 in chronic cough. In May, 2020, both Phase 3 studies of gefapixant in chronic cough reached their primary endpoint of reduction of hourly cough frequency. While full efficacy and safety data have yet to be released, gefapixant safety profile was reported to be similar to previous Phase 2 studies."